BRAF and metastatic melanoma: In addition, the side effect profile was mostly similar to that of cohort B, BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and in light of these promising results, combination dabrafenib and trametinib was approved by the US FDA for patients with metastatic melanoma and BRAF V600E mutation.